| abstract |
The present invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases, including gastrointestinal disorders, inflammation or cancer (eg, gastrointestinal cancer). The peptide can be administered alone or in conjunction with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorders can be classified as irritable bowel syndrome, constipation or hyperacidity. The gastrointestinal disease can be classified as either inflammatory bowel disease or other GI condition (including Crohn's disease and ulcerative colitis) and cancer. |